Pharma and diagnostics companies need to strengthen alignment in Alzheimer’s disease research-to help turn science and data into actionable medical innovations.
Edward I. Ginns, MD, PhD
Advertisement
Articles by Edward I. Ginns, MD, PhD
Advertisement
Latest Updated Articles
Closer Pharma-Diagnostic Collaboration is Key to Alzheimer’s Drug R&DPublished: November 1st 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Global Breast Cancer Trials Show Progress in Diversity, But Gaps Remain
2
Bringing Clinical Trials Into the Digital Era with eConsent
3
ACT Brief: AI Innovations, Vision Trial Breakthroughs, and a Major Industry Acquisition
4
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
